Published in Proc Natl Acad Sci U S A on September 15, 1998
Proliferating cells express mRNAs with shortened 3' untranslated regions and fewer microRNA target sites. Science (2008) 11.33
Formation of mRNA 3' ends in eukaryotes: mechanism, regulation, and interrelationships with other steps in mRNA synthesis. Microbiol Mol Biol Rev (1999) 11.32
Widespread shortening of 3'UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell (2009) 10.50
Symplekin and multiple other polyadenylation factors participate in 3'-end maturation of histone mRNAs. Genes Dev (2005) 3.43
hnRNP F influences binding of a 64-kilodalton subunit of cleavage stimulation factor to mRNA precursors in mouse B cells. Mol Cell Biol (2001) 2.91
3' end mRNA processing: molecular mechanisms and implications for health and disease. EMBO J (2008) 2.67
Downstream sequence elements with different affinities for the hnRNP H/H' protein influence the processing efficiency of mammalian polyadenylation signals. Nucleic Acids Res (2002) 2.00
Two distinct forms of the 64,000 Mr protein of the cleavage stimulation factor are expressed in mouse male germ cells. Proc Natl Acad Sci U S A (1999) 1.71
Global changes in processing of mRNA 3' untranslated regions characterize clinically distinct cancer subtypes. Cancer Res (2009) 1.70
The hnRNPs F and H2 bind to similar sequences to influence gene expression. Biochem J (2006) 1.62
Knock-down of 25 kDa subunit of cleavage factor Im in Hela cells alters alternative polyadenylation within 3'-UTRs. Nucleic Acids Res (2006) 1.26
U1A inhibits cleavage at the immunoglobulin M heavy-chain secretory poly(A) site by binding between the two downstream GU-rich regions. Mol Cell Biol (2004) 1.22
Regulation of nuclear poly(A) addition controls the expression of immunoglobulin M secretory mRNA. EMBO J (2001) 1.14
B-cell and plasma-cell splicing differences: a potential role in regulated immunoglobulin RNA processing. RNA (2003) 1.12
Alternative mRNA polyadenylation in eukaryotes: an effective regulator of gene expression. Wiley Interdiscip Rev RNA (2011) 1.06
Regulation of human papillomavirus type 31 polyadenylation during the differentiation-dependent life cycle. J Virol (1999) 1.06
Interactions of CstF-64, CstF-77, and symplekin: implications on localisation and function. Mol Biol Cell (2010) 1.04
The Drosophila homologue of the 64 kDa subunit of cleavage stimulation factor interacts with the 77 kDa subunit encoded by the suppressor of forked gene. Nucleic Acids Res (2000) 1.02
A complex containing the CPSF73 endonuclease and other polyadenylation factors associates with U7 snRNP and is recruited to histone pre-mRNA for 3'-end processing. Mol Cell Biol (2012) 1.01
Cordycepin Induced MA-10 Mouse Leydig Tumor Cell Apoptosis through Caspase-9 Pathway. Evid Based Complement Alternat Med (2010) 0.90
Dynamic nature of cleavage bodies and their spatial relationship to DDX1 bodies, Cajal bodies, and gems. Mol Biol Cell (2005) 0.89
CstF-64 supports pluripotency and regulates cell cycle progression in embryonic stem cells through histone 3' end processing. Nucleic Acids Res (2014) 0.88
The hinge domain of the cleavage stimulation factor protein CstF-64 is essential for CstF-77 interaction, nuclear localization, and polyadenylation. J Biol Chem (2009) 0.88
Isolation and characterization of polyadenylation complexes assembled in vitro. RNA (2000) 0.87
Spermatogenetic but not immunological defects in mice lacking the τCstF-64 polyadenylation protein. J Reprod Immunol (2011) 0.86
Preferential selection of MnSOD transcripts in proliferating normal and cancer cells. Oncogene (2011) 0.86
Binding of human SLBP on the 3'-UTR of histone precursor H4-12 mRNA induces structural rearrangements that enable U7 snRNA anchoring. Nucleic Acids Res (2006) 0.85
Alternative polyadenylation regulates CELF1/CUGBP1 target transcripts following T cell activation. Gene (2014) 0.84
CstF64: cell cycle regulation and functional role in 3' end processing of replication-dependent histone mRNAs. Mol Cell Biol (2014) 0.84
The polyadenylation code: a unified model for the regulation of mRNA alternative polyadenylation. J Zhejiang Univ Sci B (2014) 0.82
Alterations in polyadenylation and its implications for endocrine disease. Front Endocrinol (Lausanne) (2013) 0.81
ERK is a novel regulatory kinase for poly(A) polymerase. Nucleic Acids Res (2007) 0.79
The Influence of SV40 polyA on Gene Expression of Baculovirus Expression Vector Systems. PLoS One (2015) 0.75
The Cstf2t Polyadenylation Gene Plays a Sex-Specific Role in Learning Behaviors in Mice. PLoS One (2016) 0.75
Liver regeneration. Science (1997) 12.80
Mechanism and regulation of mRNA polyadenylation. Genes Dev (1997) 7.48
Alternative poly(A) site selection in complex transcription units: means to an end? Nucleic Acids Res (1997) 5.64
The polyadenylation factor CstF-64 regulates alternative processing of IgM heavy chain pre-mRNA during B cell differentiation. Cell (1996) 4.93
Hrp1, a sequence-specific RNA-binding protein that shuttles between the nucleus and the cytoplasm, is required for mRNA 3'-end formation in yeast. Genes Dev (1997) 3.47
A 64 kd nuclear protein binds to RNA segments that include the AAUAAA polyadenylation motif. Cell (1988) 3.44
A multisubunit factor, CstF, is required for polyadenylation of mammalian pre-mRNAs. Genes Dev (1990) 3.43
Transcription factor TFIID recruits factor CPSF for formation of 3' end of mRNA. Nature (1997) 3.39
RNA recognition by the human polyadenylation factor CstF. Mol Cell Biol (1997) 2.84
The human U1A snRNP protein regulates polyadenylation via a direct interaction with poly(A) polymerase. Cell (1994) 2.70
Characterization of the multisubunit cleavage-polyadenylation specificity factor from calf thymus. J Biol Chem (1992) 2.51
Interaction between the U1 snRNP-A protein and the 160-kD subunit of cleavage-polyadenylation specificity factor increases polyadenylation efficiency in vitro. Genes Dev (1996) 2.33
Purification of the cleavage and polyadenylation factor involved in the 3'-processing of messenger RNA precursors. J Biol Chem (1991) 2.25
Human pre-mRNA cleavage factor Im is related to spliceosomal SR proteins and can be reconstituted in vitro from recombinant subunits. Mol Cell (1998) 2.20
Regulated production of mu m and mu s mRNA requires linkage of the poly(A) addition sites and is dependent on the length of the mu s-mu m intron. Proc Natl Acad Sci U S A (1986) 2.19
Relative position and strengths of poly(A) sites as well as transcription termination are critical to membrane versus secreted mu-chain expression during B-cell development. Genes Dev (1987) 2.07
The FIP1 gene encodes a component of a yeast pre-mRNA polyadenylation factor that directly interacts with poly(A) polymerase. Cell (1995) 2.06
A polyadenylation factor subunit is the human homologue of the Drosophila suppressor of forked protein. Nature (1994) 2.03
Purification and characterization of human cleavage factor Im involved in the 3' end processing of messenger RNA precursors. J Biol Chem (1996) 1.88
Control of thymidylate synthase mRNA content and gene transcription in an overproducing mouse cell line. Mol Cell Biol (1985) 1.70
Cell-cycle related regulation of poly(A) polymerase by phosphorylation. Nature (1996) 1.69
Regulation of poly(A) site use during mouse B-cell development involves a change in the binding of a general polyadenylation factor in a B-cell stage-specific manner. Mol Cell Biol (1995) 1.66
RNA ligands selected by cleavage stimulation factor contain distinct sequence motifs that function as downstream elements in 3'-end processing of pre-mRNA. J Biol Chem (1997) 1.54
Effect of cell proliferation on levels and diversity of poly(A)-containing mRNA. Cell (1976) 1.53
Transcriptional regulation during B cell development. Annu Rev Immunol (1998) 1.52
Human B lymphocytes: phenotype, proliferation, and differentiation. Adv Immunol (1992) 1.45
A human polyadenylation factor is a G protein beta-subunit homologue. J Biol Chem (1992) 1.44
Regulated immunoglobulin (Ig) RNA processing does not require specific cis-acting sequences: non-Ig RNA can be alternatively processed in B cells and plasma cells. Mol Cell Biol (1994) 1.36
Cell-specific expression of secreted versus membrane forms of immunoglobulin gamma 2b mRNA involves selective use of alternate polyadenylation sites. Mol Cell Biol (1985) 1.34
Terminal riboadenylate transferase in human lymphocytes. Nature (1974) 1.22
Nuclear RNA polymerase activities and poly(A)-containing mRNA accumulation in cultured AKR mouse embryo cells stimulated to proliferate. Exp Cell Res (1977) 1.20
Clonal differences in response to T cell replacing factor (TRF) for IgM secretion and TRF receptors in a human B lymphoblast cell line. Eur J Immunol (1983) 1.18
Regulated expression of the mouse gamma 2b Ig H chain gene is influenced by polyA site order and strength. J Immunol (1992) 1.18
Effect of B cell differentiation factor (BCDF) on biosynthesis and secretion of immunoglobulin molecules in human B cell lines. J Immunol (1985) 1.15
Regulation of differential processing of mouse immunoglobulin mu heavy-chain mRNA. Nucleic Acids Res (1987) 1.14
Plasma cell-regulated polyadenylation at the Ig gamma 2b secretion-specific poly(A) site. J Immunol (1992) 1.09
Role of IL-12 in human B lymphocyte proliferation and differentiation. J Immunol (1995) 1.07
Increased rate of RNA-polyadenylation. An early response in Concanavalin A activated lymphocytes. Exp Cell Res (1978) 1.07
Inducible nuclear factors binding the IgM heavy chain pre-mRNA secretory poly(A) site. Eur J Immunol (1996) 1.05
Phosphatidylinositol 3-kinase activation in normal human B lymphocytes. J Immunol (1996) 1.04
B-lineage regulated polyadenylation occurs on weak poly(A) sites regardless of sequence composition at the cleavage and downstream regions. Nucleic Acids Res (1996) 1.03
A nonimmunoglobulin transgene and the endogenous immunoglobulin mu gene are coordinately regulated by alternative RNA processing during B-cell maturation. Mol Cell Biol (1998) 1.00
Identification of an activity in B-cell extracts that selectively impairs the formation of an immunoglobulin mu s poly(A) site processing complex. Mol Cell Biol (1995) 0.96
The binding of a subunit of the general polyadenylation factor cleavage-polyadenylation specificity factor (CPSF) to polyadenylation sites changes during B cell development. Nucleic Acids Symp Ser (1995) 0.90
A sensitive and simple method for determination of IgM in cerebrospinal fluid by a solid-phase enzyme-immunoassay. Comparison of two different methods. J Neurol Sci (1985) 0.81
Characterization of a novel Bax-associated protein expressed in hemopoietic tissues and regulated during thymocyte apoptosis. J Immunol (1998) 0.79
Comprehensive discharge planning and home follow-up of hospitalized elders: a randomized clinical trial. JAMA (1999) 11.19
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med (1988) 8.90
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med (1985) 8.21
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med (1987) 7.33
The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ (2011) 5.95
Alternative poly(A) site selection in complex transcription units: means to an end? Nucleic Acids Res (1997) 5.64
Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med (1990) 5.27
Home births in England and Wales, 1979: perinatal mortality according to intended place of delivery. Br Med J (Clin Res Ed) (1984) 4.91
Antigen-specific T-cell factor in cell cooperation. Mapping within the I region of the H-2 complex and ability to cooperate across allogeneic barriers. J Exp Med (1975) 4.64
Antigen-specific T-cell factor in cell cooperation: physical properties and mapping in the left-hand (K) half of H-2. J Exp Med (1974) 4.10
Activation of auditory cortex during silent lipreading. Science (1997) 3.94
Diagnostic assays and sampling protocols for the detection of Batrachochytrium dendrobatidis. Dis Aquat Organ (2007) 3.78
Mutants of Escherichia coli with altered deoxyribonucleases. I. Isolation and characterization of mutants for exonuclease 3. J Mol Biol (1972) 3.65
Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg (1989) 3.58
Evidence from functional magnetic resonance imaging of crossmodal binding in the human heteromodal cortex. Curr Biol (2000) 3.48
The metabolism of a poly(A) minus mRNA fraction in HeLa cells. Cell (1974) 3.17
NIH conference. Hepatocellular carcinoma. Ann Intern Med (1988) 2.94
Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med (1996) 2.92
HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene (2010) 2.91
hnRNP F influences binding of a 64-kilodalton subunit of cleavage stimulation factor to mRNA precursors in mouse B cells. Mol Cell Biol (2001) 2.91
HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia (2010) 2.83
In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol (1985) 2.73
Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med (1996) 2.69
The human GNAS1 gene is imprinted and encodes distinct paternally and biallelically expressed G proteins. Proc Natl Acad Sci U S A (1998) 2.50
Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res (1981) 2.49
The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ (2009) 2.30
Epidemiological, social, diagnostic and economic evaluation of population screening for genital chlamydial infection. Health Technol Assess (2007) 2.23
Mass screening for mutants with altered DNases by microassay techniques. Methods Enzymol (1974) 2.18
Place of delivery: a review. Br J Obstet Gynaecol (1986) 2.13
Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu Rev Immunol (1986) 2.08
Tularemia in North Carolina, 1965-1990. N C Med J (1995) 2.08
Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res (1997) 2.08
Managing alcohol-related problems in the primary care setting. Nurse Pract (1999) 2.04
A transgene containing lacZ inserted into the dystonia locus is expressed in neural tube. Nature (1988) 2.02
HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. J Exp Med (1996) 1.99
Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma. J Exp Med (1988) 1.98
Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst (1993) 1.91
The chlamydia screening studies: rationale and design. Sex Transm Infect (2004) 1.83
The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors. J Immunol (1980) 1.81
IL-6/IFN-beta-2 as a circulating hormone. Induction by cytokine administration in humans. J Immunol (1989) 1.75
Membrane-bound polyribosomes in HeLa cells: association of polyadenylic acid with membranes. J Mol Biol (1974) 1.70
Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. J Immunol (1993) 1.69
Response amplification in sensory-specific cortices during crossmodal binding. Neuroreport (1999) 1.68
Regulation of poly(A) site use during mouse B-cell development involves a change in the binding of a general polyadenylation factor in a B-cell stage-specific manner. Mol Cell Biol (1995) 1.66
Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest (1996) 1.64
Primary care physician supply and colorectal cancer. J Fam Pract (2001) 1.64
Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res (1994) 1.64
Choice and chance in low risk maternity care. BMJ (1991) 1.63
Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer (1986) 1.60
A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy. J Clin Oncol (1990) 1.59
Expression of the thyroid hormone receptor gene, erbAalpha, in B lymphocytes: alternative mRNA processing is independent of differentiation but correlates with antisense RNA levels. Nucleic Acids Res (1997) 1.55
Early versus delayed shoulder motion following axillary dissection: a randomized prospective study. Ann Surg (1981) 1.54
Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res (2001) 1.51
Production and fluorescence-activated cell sorting of Escherichia coli expressing a functional antibody fragment on the external surface. Proc Natl Acad Sci U S A (1993) 1.51
In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J Immunol (1985) 1.50
Acyclic antimetabolite therapy of experimental herpes simplex keratitis. Am J Ophthalmol (1978) 1.50
A prospective randomized trial evaluating colloid versus crystalloid resuscitation in the treatment of the vascular leak syndrome associated with interleukin-2 therapy. J Immunother Emphasis Tumor Immunol (1994) 1.49
Coping style and depression influence the healing of diabetic foot ulcers: observational and mechanistic evidence. Diabetologia (2010) 1.47
Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol (1988) 1.46
Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol (1989) 1.46
TOM, a new aromatic degradative plasmid from Burkholderia (Pseudomonas) cepacia G4. Appl Environ Microbiol (1995) 1.44
In vitro growth of cytotoxic human lymphocytes. II. Use of T cell growth factor (TCGF) to clone human T cells. J Immunol (1980) 1.44
The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med (1987) 1.44
In vitro complex formation and biodistribution of mouse antitumor monoclonal antibody in cancer patients. J Nucl Med (1989) 1.43
Viral interleukin 10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local anergy to allogeneic and syngeneic tumors. J Exp Med (1995) 1.42
HeLa cell poly(A)- mRNA codes for a subset of poly(A)+ mRNA-directed proteins with an actin as a major product. Proc Natl Acad Sci U S A (1977) 1.42
In vivo induction of IL-6 by administration of exogenous cytokines and detection of de novo serum levels of IL-6 in tumor-bearing mice. J Immunol (1989) 1.41
A comparison of apparent mRNA half-life using kinetic labeling techniques vs decay following administration of transcriptional inhibitors. Anal Biochem (1991) 1.40
Predictors of proximal vs. distal colorectal cancers. Dis Colon Rectum (2001) 1.40
Human gene transfer: characterization of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man. Proc Natl Acad Sci U S A (1990) 1.36
In vitro growth of cytotoxic human lymphocytes. III. The preparation of lectin-free T cell growth factor (TCGF) and an analysis of its activity. J Immunol (1981) 1.36
Human intestinal Vdelta1+ lymphocytes recognize tumor cells of epithelial origin. J Exp Med (1996) 1.36
Atrial myxoma: a review of the neurological complications, metastases, and recurrences. J Neurol Neurosurg Psychiatry (1978) 1.35
Cell-specific expression of secreted versus membrane forms of immunoglobulin gamma 2b mRNA involves selective use of alternate polyadenylation sites. Mol Cell Biol (1985) 1.34
IgG2a-producing variants of an IgG2b-producing mouse myeloma cell line. J Exp Med (1978) 1.34
Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Ann Surg (1998) 1.32
Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med (1996) 1.32
Mass spectrometric identification of increased C16 ceramide levels during apoptosis. J Biol Chem (1999) 1.32
Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther (1996) 1.31
Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome. J Immunol (1988) 1.30
Retrovirus-mediated transfer of viral IL-10 gene prolongs murine cardiac allograft survival. J Immunol (1996) 1.29
Lysis of human solid tumors by autologous cells sensitized in vitro to alloantigens. J Immunol (1981) 1.29
IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects. J Immunol (1998) 1.28
Regulatable systems: applications in gene therapy and replicating viruses. J Clin Invest (2000) 1.27
Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin Immunopathol (1999) 1.26
Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol (1995) 1.26
Preliminary mapping of mutations affecting exonuclease 3 in Escherichia coli K-12. J Bacteriol (1973) 1.26
Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J Immunol (1995) 1.25
Patterns of alcohol use and multiple risk behaviour by gender during early and late adolescence: the ALSPAC cohort. J Public Health (Oxf) (2012) 1.24
Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med (1995) 1.24
Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. J Immunol (1999) 1.22
The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma. J Immunol (1984) 1.22
NIH conference. New approaches to the immunotherapy of cancer using interleukin-2. Ann Intern Med (1988) 1.22
Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ. Blood (2001) 1.21
Family and carer smoking control programmes for reducing children's exposure to environmental tobacco smoke. Cochrane Database Syst Rev (2003) 1.21
Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin Cancer Res (1999) 1.20
Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. J Immunother Emphasis Tumor Immunol (1993) 1.20